Close Menu

NEW YORK – PerkinElmer said after the close of the market on Tuesday that its second quarter revenues grew 12 percent year over year as Diagnostics segment revenues were up 46 percent.

For the three months ended July 5, the company reported total revenues of $811.7 million compared to $722.5 million a year ago. It beat the consensus Wall Street estimate of $726.4 million.

Organically, revenues rose 13 percent year over year, PerkinElmer CFO Jamey Mock said on a conference call following the release of the financial results.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.